2026 Global: Cancer Biomarkers Market-Competitive Review (2032) report
Description
The 2026 Global: Cancer Biomarkers Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer biomarkers market by geography and historical trend. The scope of the report extends to sizing of the cancer biomarkers market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio‑Rad Laboratories, Abbott Laboratories, Guardant Health, Exact Sciences, Siemens Healthineers, and Myriad Genetics are widely recognized among the ten major companies shaping the cancer biomarkers market due to their extensive product portfolios, strategic investments, and clinical partnerships. Roche leads the sector with a broad diagnostics franchise and companion diagnostic capabilities that integrate immunohistochemistry, in situ hybridization, and molecular assays for oncology decision-making. Thermo Fisher supplies complete workflows—reagents, instruments, and informatics—for genomic and proteomic biomarker discovery and clinical testing and has expanded its proteomics and assay breadth through acquisitions that strengthen multiplex and high‑throughput offerings. QIAGEN focuses on sample-to‑insight molecular diagnostic solutions and partnerships that enhance its oncology panels and companion diagnostic reach across clinical and research laboratories. Illumina’s next‑generation sequencing platforms underpin many genomic biomarker applications and enable broad adoption of comprehensive genomic profiling, liquid biopsy research, and large‑scale oncology sequencing initiatives. Bio‑Rad advances sensitive detection platforms such as droplet digital PCR used for circulating tumor DNA (ctDNA) and rare mutation quantification, supporting both research and clinical monitoring workflows. Abbott’s diagnostics portfolio spans immunoassays and molecular platforms for common cancer markers and routine clinical laboratory integration, reinforcing its role in widely used tumor marker testing and point‑of‑care workflows. Guardant Health is a leader in liquid biopsy and ctDNA testing with commercially deployed assays for comprehensive genomic profiling and disease monitoring that accelerate non‑invasive oncology diagnostics and real‑time treatment guidance. Exact Sciences has concentrated on screening and early detection with non‑invasive tests for colorectal and other cancers, coupling molecular biomarker assays with commercialization strategies aimed at population screening and payer access. Siemens Healthineers provides imaging and laboratory diagnostics that integrate biomarker-driven workflows across radiology and in vitro diagnostics, positioning the company to support multimodal oncology diagnostics and precision medicine programs. Myriad Genetics contributes hereditary cancer testing and companion diagnostic assays, emphasizing germline and actionable somatic biomarkers used for risk assessment, therapeutic selection, and pharmacogenomic insights in oncology care.
Collectively these firms drive market growth through innovation in liquid biopsy, next‑generation sequencing, multiplex proteomics, and integrated diagnostic platforms that enable earlier detection, improved prognostication, and therapy selection. Strategic actions—Roche’s sustained investment in companion diagnostics and clinical algorithms, Thermo Fisher’s acquisitions expanding proteomics and assay menus, Illumina’s partnerships to scale bioinformatics, and Guardant’s regulatory progress in multi‑cancer ctDNA testing—illustrate how product development, M&A, and regulatory engagement accelerate clinical translation of biomarkers. The competitive landscape also features differentiation by end‑user focus: centralized reference labs and hospital systems adopt high‑complexity NGS and proteomic panels for comprehensive profiling, while point‑of‑care and routine chemistry/immunoassay players maintain volume testing for established tumor markers. Pricing pressures, reimbursement complexity, and regulatory scrutiny of laboratory‑developed tests incentivize consolidation and partnerships between platform providers, specialty diagnostics firms, and clinical laboratories to achieve scale, validation rigor, and payer acceptance.
Market leadership among these ten companies is reinforced by global distribution networks, clinical trial support, and substantial R&D spending that together accelerate biomarker discovery and commercialization for oncology. Advances in assay sensitivity (ddPCR, NGS), proteomic multiplexing, and AI‑driven biomarker discovery are expanding the addressable market for predictive, prognostic, and diagnostic biomarkers, while firms with integrated offerings—from sample processing through reporting and clinical decision support—are best positioned to capture clinical adoption and reimbursement.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer biomarkers market by geography and historical trend. The scope of the report extends to sizing of the cancer biomarkers market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio‑Rad Laboratories, Abbott Laboratories, Guardant Health, Exact Sciences, Siemens Healthineers, and Myriad Genetics are widely recognized among the ten major companies shaping the cancer biomarkers market due to their extensive product portfolios, strategic investments, and clinical partnerships. Roche leads the sector with a broad diagnostics franchise and companion diagnostic capabilities that integrate immunohistochemistry, in situ hybridization, and molecular assays for oncology decision-making. Thermo Fisher supplies complete workflows—reagents, instruments, and informatics—for genomic and proteomic biomarker discovery and clinical testing and has expanded its proteomics and assay breadth through acquisitions that strengthen multiplex and high‑throughput offerings. QIAGEN focuses on sample-to‑insight molecular diagnostic solutions and partnerships that enhance its oncology panels and companion diagnostic reach across clinical and research laboratories. Illumina’s next‑generation sequencing platforms underpin many genomic biomarker applications and enable broad adoption of comprehensive genomic profiling, liquid biopsy research, and large‑scale oncology sequencing initiatives. Bio‑Rad advances sensitive detection platforms such as droplet digital PCR used for circulating tumor DNA (ctDNA) and rare mutation quantification, supporting both research and clinical monitoring workflows. Abbott’s diagnostics portfolio spans immunoassays and molecular platforms for common cancer markers and routine clinical laboratory integration, reinforcing its role in widely used tumor marker testing and point‑of‑care workflows. Guardant Health is a leader in liquid biopsy and ctDNA testing with commercially deployed assays for comprehensive genomic profiling and disease monitoring that accelerate non‑invasive oncology diagnostics and real‑time treatment guidance. Exact Sciences has concentrated on screening and early detection with non‑invasive tests for colorectal and other cancers, coupling molecular biomarker assays with commercialization strategies aimed at population screening and payer access. Siemens Healthineers provides imaging and laboratory diagnostics that integrate biomarker-driven workflows across radiology and in vitro diagnostics, positioning the company to support multimodal oncology diagnostics and precision medicine programs. Myriad Genetics contributes hereditary cancer testing and companion diagnostic assays, emphasizing germline and actionable somatic biomarkers used for risk assessment, therapeutic selection, and pharmacogenomic insights in oncology care.
Collectively these firms drive market growth through innovation in liquid biopsy, next‑generation sequencing, multiplex proteomics, and integrated diagnostic platforms that enable earlier detection, improved prognostication, and therapy selection. Strategic actions—Roche’s sustained investment in companion diagnostics and clinical algorithms, Thermo Fisher’s acquisitions expanding proteomics and assay menus, Illumina’s partnerships to scale bioinformatics, and Guardant’s regulatory progress in multi‑cancer ctDNA testing—illustrate how product development, M&A, and regulatory engagement accelerate clinical translation of biomarkers. The competitive landscape also features differentiation by end‑user focus: centralized reference labs and hospital systems adopt high‑complexity NGS and proteomic panels for comprehensive profiling, while point‑of‑care and routine chemistry/immunoassay players maintain volume testing for established tumor markers. Pricing pressures, reimbursement complexity, and regulatory scrutiny of laboratory‑developed tests incentivize consolidation and partnerships between platform providers, specialty diagnostics firms, and clinical laboratories to achieve scale, validation rigor, and payer acceptance.
Market leadership among these ten companies is reinforced by global distribution networks, clinical trial support, and substantial R&D spending that together accelerate biomarker discovery and commercialization for oncology. Advances in assay sensitivity (ddPCR, NGS), proteomic multiplexing, and AI‑driven biomarker discovery are expanding the addressable market for predictive, prognostic, and diagnostic biomarkers, while firms with integrated offerings—from sample processing through reporting and clinical decision support—are best positioned to capture clinical adoption and reimbursement.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.